Prisma Health-Upstate
Prisma Health-Upstate was paid $13.11M by Medicaid between Jan 2018 and Dec 2024, across 196 billing codes. Its largest line is 36415, Collection of venous blood by venipuncture — 12% of everything it billed.
CLINTON, SC 29325
Next to other General Acute Care Hospital providers in South Carolina
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 64,279 | $1.53M | |
| 2019 | 82,452 | $1.68M | |
| 2020 | 72,143 | $1.51M | |
| 2021 | 94,752 | $1.93M | |
| 2022 | 98,984 | $2.30M | |
| 2023 | 94,962 | $2.49M | |
| 2024incomplete | 67,540 | $1.69M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 36415 | Collection of venous blood by venipuncture | 12% | 19,028 | 13,744 | $1.53M |
| 80053 | Comprehensive metabolic panel | 10% | 24,304 | 21,418 | $1.36M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.6% | 27,962 | 26,060 | $1.13M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.6% | 6,504 | 6,303 | $869K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 4.2% | 5,983 | 5,712 | $555K |
| 80048 | Basic metabolic panel (calcium, ionized) | 4.1% | 14,087 | 10,980 | $537K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 3.7% | 13,093 | 8,192 | $487K |
| 81025 | 2.9% | 10,406 | 9,721 | $382K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.7% | 10,644 | 6,861 | $354K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.6% | 3,241 | 2,950 | $337K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.5% | 778 | 364 | $328K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.5% | 8,715 | 6,745 | $326K |
184 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.1% | 9,711 | $281K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 7,914 | $280K |
| 81001 | 1.9% | 18,837 | $255K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 4,515 | $196K |
| 76830 | Ultrasound, transvaginal | 1.4% | 638 | $188K |
| 87070 | 1.3% | 1,183 | $169K | |
| 87081 | 1.3% | 2,643 | $166K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.3% | 10,712 | $165K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 1.2% | 3,031 | $162K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 738 | $138K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.0% | 4,676 | $131K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 12,881 | $130K |
| 99284 | Emergency room visit (serious) | <1% | 15,816 | $127K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 3,695 | $115K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,253 | $107K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,727 | $97K |
| 87077 | <1% | 3,917 | $91K | |
| 73630 | <1% | 1,674 | $86K | |
| 85018 | <1% | 14,016 | $82K | |
| 97597 | <1% | 2,027 | $81K | |
| 73610 | <1% | 1,376 | $78K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,521 | $74K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,095 | $73K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,503 | $68K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 3,203 | $65K |
| 81003 | <1% | 16,304 | $58K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,764 | $58K |
| 73130 | <1% | 623 | $57K | |
| 73564 | <1% | 1,465 | $54K | |
| 71250 | <1% | 139 | $52K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 402 | $52K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,561 | $49K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 34,836 | $46K |
| 80047 | <1% | 728 | $44K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,134 | $44K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 838 | $44K |
| 99285 | Emergency room visit (most serious) | <1% | 14,360 | $44K |
| 73030 | <1% | 1,014 | $41K | |
| 87210 | <1% | 1,899 | $40K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,077 | $40K |
| 86900 | <1% | 1,090 | $39K | |
| 86850 | <1% | 550 | $34K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,592 | $32K |
| 84702 | <1% | 1,667 | $31K | |
| 73110 | <1% | 439 | $30K | |
| 80061 | Lipid panel | <1% | 7,002 | $29K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,093 | $28K |
| 74018 | <1% | 805 | $27K | |
| 87807 | <1% | 1,570 | $26K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 234 | $25K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 510 | $23K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 925 | $20K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 103 | $20K |
| 72100 | <1% | 826 | $19K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 573 | $18K |
| 93971 | <1% | 65 | $16K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,122 | $15K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 185 | $14K |
| 97162 | <1% | 1,018 | $14K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 425 | $14K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 948 | $13K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 89 | $13K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,021 | $13K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 814 | $13K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,747 | $13K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,718 | $12K |
| G0378 | Hospital observation service, per hour | <1% | 2,902 | $12K |
| 84439 | <1% | 1,687 | $11K | |
| 97032 | <1% | 98 | $11K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,778 | $10K |
| 85027 | <1% | 4,075 | $10K | |
| 86308 | <1% | 390 | $10K | |
| 93017 | <1% | 63 | $8K | |
| 82043 | <1% | 1,081 | $8K | |
| 86780 | <1% | 187 | $7K | |
| 82607 | <1% | 925 | $7K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 590 | $7K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,815 | $6K |
| 87428 | <1% | 87 | $6K | |
| 80076 | <1% | 1,841 | $6K | |
| 82565 | <1% | 59 | $6K | |
| J3490 | Unclassified drugs | <1% | 3,513 | $5K |
| 83690 | <1% | 6,802 | $5K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,133 | $5K |
| 84484 | <1% | 7,168 | $5K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,382 | $4K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 307 | $4K |
| 85610 | <1% | 3,453 | $4K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 27 | $4K |
| 73502 | <1% | 147 | $3K | |
| 74022 | <1% | 305 | $3K | |
| 86803 | <1% | 831 | $3K | |
| 12001 | <1% | 41 | $3K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 991 | $3K |
| 83540 | <1% | 979 | $3K | |
| 82728 | <1% | 486 | $3K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 993 | $3K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,790 | $3K |
| 85007 | <1% | 1,140 | $3K | |
| 82947 | <1% | 357 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,293 | $3K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,679 | $3K |
| 85379 | <1% | 1,685 | $3K | |
| 86580 | <1% | 205 | $2K | |
| 73080 | <1% | 50 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,362 | $2K |
| 86140 | <1% | 1,830 | $2K | |
| 83880 | <1% | 2,560 | $2K | |
| 73140 | <1% | 16 | $2K | |
| 87400 | <1% | 25 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,756 | $2K |
| 82570 | <1% | 1,032 | $2K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 778 | $2K |
| 83735 | <1% | 7,474 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,062 | $1K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,422 | $1K |
| 96376 | <1% | 3,426 | $1K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 607 | $1K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,147 | $1K |
| 84145 | <1% | 1,045 | $926.49 | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 13 | $917.77 |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 50 | $897.69 |
| 85730 | <1% | 1,056 | $809.47 | |
| 93976 | <1% | 766 | $762.84 | |
| 80143 | <1% | 228 | $703.32 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 48 | $661.69 |
| 82077 | <1% | 1,315 | $654.33 | |
| 82550 | <1% | 413 | $625.79 | |
| 73562 | <1% | 13 | $511.80 | |
| 82746 | <1% | 196 | $498.47 | |
| 82803 | <1% | 308 | $480.96 | |
| 84100 | <1% | 2,091 | $465.35 | |
| 76642 | <1% | 13 | $437.73 | |
| 82962 | <1% | 23 | $423.28 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 14 | $420.18 |
| 59025 | Fetal non-stress test | <1% | 86 | $407.94 |
| 86038 | <1% | 27 | $398.89 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,307 | $393.28 |
| 81002 | <1% | 435 | $341.89 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 25 | $258.11 |
| 73590 | <1% | 28 | $253.02 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,190 | $177.27 |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 13 | $163.20 |
| 97161 | <1% | 25 | $152.54 | |
| 97166 | <1% | 61 | $147.68 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 3,710 | $144.05 |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 181 | $111.75 |
| 83605 | <1% | 3,503 | $92.39 | |
| 87040 | <1% | 1,507 | $87.50 | |
| 86480 | <1% | 17 | $82.29 | |
| 84156 | <1% | 34 | $49.34 | |
| 87186 | <1% | 3,096 | $47.17 | |
| 90715 | <1% | 238 | $40.37 | |
| 70496 | <1% | 12 | $31.95 | |
| 80179 | <1% | 113 | $13.42 | |
| 84550 | <1% | 53 | $6.88 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,495 | $6.53 |
| 85652 | <1% | 821 | $6.38 | |
| 87205 | <1% | 492 | $4.46 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 141 | $4.09 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,155 | $2.08 |
| 85651 | <1% | 490 | $0.90 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 937 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 963 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 274 | $0.00 |
| 84466 | 0% | 631 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 80 | $0.00 |
| 96367 | 0% | 130 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 49 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 229 | $0.00 |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 0% | 12 | $0.00 |
| J2300 | Injection, nalbuphine hydrochloride, per 10 mg | 0% | 134 | $0.00 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 15 | $0.00 |
| 86901 | 0% | 1,089 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 386 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 471 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 1,086 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 391 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 28 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 28 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 106 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 12 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 48 | $0.00 |
| 70498 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Prisma Health-Midlands | Columbia, SC | $74.58M |
| Prisma Health-Midlands | Columbia, SC | $68.26M |
| Prisma Health-Upstate | Greenville, SC | $25.04M |
| Prisma Health-Upstate | Greenville, SC | $21.98M |
| Prisma Health-Upstate | Greenville, SC | $19.69M |
| Prisma Health-Upstate | Seneca, SC | $15.64M |
| Prisma Health-Midlands | Columbia, SC | $11.77M |
| Prisma Health-Upstate | Greenville, SC | $10.74M |
| Greenville Health Corporation | Greenville, SC | $8.90M |
| Prisma Health-Upstate | Greenville, SC | $8.32M |
| Prisma Health-Upstate | Greenville, SC | $7.45M |
| Prisma Health University Medical Group | Greenville, SC | $7.44M |
| Prisma Health-Midlands | Coulmbia, SC | $7.43M |
| Prisma Health-Midlands | Columbia, SC | $6.88M |
| Prisma Health Tuomey | Sumter, SC | $6.84M |
| Prisma Health-Midlands | Columbia, SC | $6.77M |
| Prisma Health-Upstate | Greenville, SC | $6.37M |
| Prisma Health-Upstate | Greenville, SC | $5.00M |
| Prisma Health-Upstate | Greenville, SC | $4.65M |
| Prisma Health-Midlands | Columbia, SC | $4.63M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.